Back to Results
First PageMeta Content
Emerging technologies / Stem cells / Macular degeneration / Bevacizumab / Vascular endothelial growth factor / Ranibizumab / Cell therapy / Stem cell treatments / Retina / Biology / Medicine / Health


Document Date: 2011-12-15 20:29:03

Open Document

File Size: 554,53 KB

Share Result on Facebook

City

Melbourne / /

Company

Macular Degeneration Foundation Ltd / AMD / /

Continent

Europe / /

Country

United States / Australia / /

Currency

USD / /

Event

Product Issues / FDA Phase / /

Facility

National Eye Institute / University of Nebraska At / University of Georgetown / University of Kentucky / /

IndustryTerm

manufacturing dossier / treatment for glaucoma / treatment for many other diseases / energy / treatment for all three diseases / low energy laser / waste products / /

MedicalCondition

glaucoma / macular edema / complex disease / Macular Degeneration / heart disease / injury / Multiple Sclerosis / birth defects / Stargardt’s Disease / cancers / Alzheimer’s Disease / Disease / total blindness / diabetes / end-stage disease / uniquely human disease / diseases / equivalent diseases / low vision / inflammation / depression / cataract / tumours / /

MedicalTreatment

stem cell therapy / surgery / Surgical treatment / gene therapy / Radiation treatment / surgical treatments / brachytherapy / /

Organization

National Eye Institute / Therapeutic Goods Administration / University of Georgetown / University of Nebraska At / federal government / the University of Kentucky / /

Person

Safety / /

/

Product

Avastin / Lucentis / Copaxone / Vitamin A / This / DICER1 / US / AL32324 This drug / gene / Pazopanib This agent / genes / /

ProvinceOrState

Kentucky / Nebraska / Maryland / /

Technology

Radiation / x-ray / cell therapy / Diagnostic tests / stem cells / gene therapy / laser / /

URL

www.mdfoundation.com.au / /

SocialTag